Global Infectious Diseases Therapeutics Market - Influenza, RSV, Chlamydia, and Gonorrhoea

Global Infectious Diseases Therapeutics Market - Influenza, RSV, Chlamydia, and Gonorrhoea

Persistent Unmet Need for Treatment Fuels Novel Antiviral/Antibacterial Drug Development

RELEASE DATE
14-Feb-2014
REGION
North America
Research Code: M9B7-01-00-00-00
SKU: LS00096-NA-MR_16937
AvailableYesPDF Download

$3,950.00

Special Price $2,962.50 save 25 %

In stock
SKU
LS00096-NA-MR_16937

$3,950.00

$2,962.50save 25 %

DownloadLink
ENQUIRE NOW

Description

This research service focuses on antibiotic/antibacterial therapeutics for the treatment of infection by blood-borne (sexually transmitted) bacteria, which include Chlamydia trachomatis and Neisseria gonorrhoea as well as antiviral therapeutics for infections by vector-borne pathogens such as the influenza virus and the human respiratory syncytial virus (RSV).This research service comprises of a product and pipeline assessment for marketed and investigational products and combination regimens for the treatment of Chlamydia trachomatis, Neisseria gonorrhoeae, Influenza and RSV infections. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines, results, and epidemiology.

Table of Contents

Introduction

Introduction (continued)

Evolution of Standard of Care

Evolution of Standard of Care (continued)

Evolution of Standard of Care (continued)

Evolution of Standard of Care (continued)

Methodology and Scope

Market Overview—Segmentation

Market Overview—Segmentation (continued)

Market Overview—Segmentation (continued)

Market Overview—Segmentation (continued)

Market Overview—Segmentation (continued)

RSV—Market Segmentation

RSV—Competitive Landscape: Select Marketed Products and Products in Development

RSV—Key Marketed Products Synopsis

RSV Product Dashboard

RSV Product Dashboard (continued)

RSV—Pipeline Synopsis

RSV—Pipeline Synopsis (continued)

RSV—Major Ongoing/Recently Completed Clinical Trials

RSV—Major Ongoing/Recently Completed Clinical Trials (continued)

RSV—Major Ongoing/Recently Completed Clinical Trials (continued)

RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings

RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

RSV—Timeline of Key Events

RSV—Key Company to Watch

RSV—Key Companies with Best Practices

RSV—New Market Opportunities

RSV—New Market Opportunities (continued)

RSV—Merger, Acquisition, and Partnership Assessment

Influenza—Market Segmentation

Influenza—Competitive Landscape: Select Marketed Products and Products in Development

Influenza Antivirals—Key Marketed Products Synopsis

Influenza Antivirals—Key Marketed Products Synopsis (continued)

Influenza Antivirals—Key Marketed Products Synopsis (continued)

Influenza Antivirals—Product Dashboard

Influenza Antivirals—Product Dashboard (continued)

Influenza Antivirals—Product Dashboard (continued)

Influenza Antivirals—Pipeline Synopsis

Influenza Antivirals—Pipeline Synopsis (continued)

Influenza Antivirals—Pipeline Synopsis (continued)

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials (continued)

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Influenza Antivirals—Timeline of Key Events

Influenza Vaccines—Key Marketed Products Synopsis

Influenza Vaccines—Key Marketed Products Synopsis (continued)

Influenza Vaccines—Key Marketed Products Synopsis (continued)

Influenza Vaccines—Key Marketed Products Synopsis (continued)

Influenza Vaccines—Key Marketed Products Synopsis (continued)

Influenza Vaccines—Key Marketed Products Synopsis (continued)

Influenza Vaccines—Pipeline Synopsis

Influenza Vaccines—Pipeline Synopsis (continued)

Influenza Vaccines—Pipeline Synopsis (continued)

Influenza Vaccines—Pipeline Synopsis (continued)

Influenza Vaccines—Key Companies to Watch

Influenza Vaccines—Merger, Acquisition and Partnership Assessment

Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)

Influenza Vaccines—Merger, Acquisition and Partnership Assessment

Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)

Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)

Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)

Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)

Chlamydia—Market Segmentation

Chlamydia—Treatment Regimen

Chlamydia—Treatment Regimen (continued)

Chlamydia—Treatment Regimen (continued)

Chlamydia—Competitive Landscape: Select Marketed Products and Products in Development

Chlamydia—Key Marketed Products Synopsis

Chlamydia—Key Marketed Products Synopsis (continued)

Chlamydia—Pipeline Synopsis

Chlamydia—Major Ongoing/Recently Completed Clinical Trials

Chlamydia—Major Ongoing/Recently Completed Clinical Trials (continued)

Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings

Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Chlamydia—Timeline of Key Events

Chlamydia—Key Company to Watch

Gonorrhoea—Market Segmentation

Gonorrhoea—Treatment Regimen

Gonorrhoea—Treatment Regimen (continued)

Gonorrhoea—Treatment Regimen (continued)

Gonorrhoea—Treatment Regimen (continued)

Gonorrhoea—Competitive Landscape: Select Marketed Products and Products in Development

Gonorrhoea—Key Marketed Products Synopsis

Gonorrhoea—Key Marketed Products Synopsis (continued)

Gonorrhoea—Key Marketed Products Synopsis (continued)

Gonorrhoea—Key Marketed Products Synopsis (continued)

Gonorrhoea—Pipeline Synopsis

Gonorrhoea—Pipeline Synopsis (continued)

Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials

Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials Detailed Findings

Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)

Gonorrhoea—Timeline of Key Events

Gonorrhoea—Key Company to Watch

Legal Disclaimer

Disease Characteristics

Disease Characteristics (continued)

Disease Characteristics (continued)

Disease Characteristics (continued)

The Frost & Sullivan Story

Value Proposition

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The standard of care, microfracture, does not fulfill long-term needs for patients with chondral defects. In addition, current alternative treatment options are plagued by multiple challenges and limitations. This research service focuses on medicine in the knee cartilage repair market, providing a detailed overview of 9 key products. A product and pipeline assessment is provided for marketed and investigational autologous cell-based therapy, allogenic cell-based therapy, and non-cellular products in the global, US, and European markets. Product profiles are included for companies that are currently or imminently marketing cell-based regenerative therapies and conducting clinical trials in the United States and Europe.
More Information
No Index No
Podcast No
Author Aiswariya Chidambaram
WIP Number M9B7-01-00-00-00
Is Prebook No